Announcements Trials
Browse Landscape

Phase

Phase 3 28Phase 2 26Phase 1 6Phase 2/3 4Phase NA 3Phase 1/2 3

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2UNKNOWN 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Pancreatic Neoplasms 97Neoplasms 28Carcinoma, Non-Small-Cell Lung 27Neoplasm Metastasis 23Urinary Bladder Neoplasms 17Colorectal Neoplasms 17Sarcoma 15Lung Neoplasms 14Biliary Tract Neoplasms 13Ovarian Neoplasms 12Lymphoma, Large B-Cell, Diffuse 12Breast Neoplasms 12Lymphoma 10Cholangiocarcinoma 10Recurrence 9Hodgkin Disease 8Carcinoma, Transitional Cell 8Adenocarcinoma 8Lymphoma, Non-Hodgkin 7Triple Negative Breast Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 6Lymphoma, Follicular 6Stomach Neoplasms 5Small Cell Lung Carcinoma 5Rectal Neoplasms 5Gastrointestinal Neoplasms 5Colonic Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Multiple Myeloma 4Lymphoma, T-Cell, Peripheral 4

Interventions

toripalimab 5Cisplatin 5pembrolizumab 3Radiotherapy, Intensity-Modulated 3Heavy Ion Radiotherapy 3Gemcitabine 3anlotinib 2spartalizumab 1nedaplatin 1icotinib 1fludarabine phosphate 1fludarabine 1famitinib 1donafenib 1Vorinostat 1TP protocol 1Sodium Chloride 1SHR-1701 1Quality of Life 1Paclitaxel 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Interleukin-2 1Immunotherapy, Adoptive 1Gefitinib 1Cyclophosphamide 1Cetuximab 1Celecoxib 1Bevacizumab 1Adjuvants, Pharmaceutic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Nasopharyngeal Carcinoma × Gemcitabine × Clear all
NCT06802835 2026-05-11

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 1/2 Recruiting
148 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT05898256 2023-06-12

Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

Guangxi Medical University

Phase 1/2 Not yet recruiting
20 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT03639467 2018-09-18

Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma

ChineseAMS

Phase 1/2 Unknown
40 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡